A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia

This trial is testing a combination of two drugs — gilteritinib and momelotinib — for patients with relapsed or treatment-resistant acute myeloid leukemia (AML) that has a mutation in the FLT3 gene. **You may be eligible if...** - You are 18 or older - You have AML that has a FLT3 mutation (either FLT3-ITD or FLT3 D835/D836) - Your AML has come back or stopped responding to previous treatment - Your liver and kidneys are functioning adequately - You are willing to use contraception during and for 4 months after the study **You may NOT be eligible if...** - You have a congenital heart condition called long QT syndrome - Your heart rhythm test (ECG) shows a QTcF greater than 450 ms - Your kidney function is significantly impaired (creatinine clearance below 30 mL/min) Talk to your doctor to see if this trial is right for you.